Oligonucleotide API Market Size & Share, by API type {Short Interfering RNA (siRNA), Antisense Oligonucleotides, Phosphorodiamidate Morpholino Oligonucleotides (PMO), Aptamers, CpG Oligonucleotides, MiRNA API}; Marketing Status (Marketed, Clinical Trials); End-user (Pharmaceutical Companies, Biotechnology Companies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4308
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Companies Dominating the Oligonucleotide API Landscape

top-features-companies
    • Ionis Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Jazz Pharmaceuticals plc
    • BIOGEN INC.
    • Sarepta Therapeutics, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Corden Pharma International GmbH
    • Nitto Denko Avecia, Inc.
    • Merck KGaA
    • Ajinomoto Co., Inc.
    • Kaneka Eurogentec S.A.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Ionis Pharmaceuticals, Inc. in collaboration with Biogen Inc., has announced the results of the investigation of the use of antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).

  • Jazz Pharmaceuticals plc has announced that its Zepzelca (Lurbinectedin) has been approved by the U.S. Food and Drug Administration(FDA), for treating adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4308
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Globally rising prevalence of cancer and neurodegenerative diseases, growth in percentage of API manufacturing facilities, and growing expenditures on healthcare throughout the world are the major factors driving the market growth.

The market is anticipated to attain a CAGR of ~10% over the forecast period, i.e., 2023-2035.

High production of waste associated with oligonucleotide, and complex procedure of manufacturing are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, BIOGEN INC, Sarepta Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Corden Pharma International GmbH, Nitto Denko Avecia, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by API type, marketing status, end-user, and by region.

The pharmaceutical companies segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying